Skip to main content
Medical information Clinical review pending

Genetic Testing

ANO5 Gene Limbgirdle Muscular Dystrophy Autosomal Recessive Type 2L Genetic Test

Genetic test to identify mutations in the ANO5 gene associated with Limb-Girdle Muscular Dystrophy Type 2L (LGMD2L). This test uses Next-Generation Sequencing (NGS) on a blood sample to help diagnose this inherited muscle disorder.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample (typically 5-10ml) collected in an EDTA tube.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for the blood draw. However, a clinical history review and genetic counseling session are recommended before the test.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ANO5 Gene Limbgirdle Muscular Dystrophy Autosomal Recessive Type 2L Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals experiencing progressive muscle weakness, particularly in the shoulder and hip areas.
  • ✓Patients with a family history of Limb-Girdle Muscular Dystrophy.
  • ✓Diagnosis confirmation when clinical symptoms suggest LGMD2L.
  • ✓Genetic counseling for families affected by LGMD2L.
  • ✓Individuals seeking to understand the genetic basis of their muscle weakness.
02

In plain language

What this test helps you understand

This test helps confirm a diagnosis of ANO5-related Limb-Girdle Muscular Dystrophy Type 2L (LGMD2L). Identifying the specific genetic mutation can aid in understanding the disease progression, guiding management strategies, and informing family members about potential genetic risks.
The ANO5 Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2L NGS Genetic DNA Test is a diagnostic tool used to identify mutations in the ANO5 gene. This gene is linked to a specific type of limb-girdle muscular dystrophy (LGMD2L), an inherited condition causing progressive muscle weakness, primarily affecting the muscles around the hips and shoulders. Early and accurate diagnosis through genetic testing is important for understanding the condition, managing symptoms, and exploring potential treatment options. This test utilizes Next-Generation Sequencing (NGS) technology to analyze DNA from a blood sample, looking for specific genetic changes in the ANO5 gene. It is recommended for individuals suspected of having LGMD2L based on clinical symptoms or family history.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for the blood draw. However, a clinical history review and genetic counseling session are recommended before the test.
SampleA blood sample (typically 5-10ml) collected in an EDTA tube.
MethodologyNext-Generation Sequencing (NGS) of the ANO5 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the ANO5 gene. It will not detect mutations in other genes that can cause Limb-Girdle Muscular Dystrophy or other neuromuscular disorders. A negative result does not completely rule out LGMD2L if the clinical suspicion is high, as rare variants may not be detected. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

LGMD2L is an inherited muscle disorder caused by mutations in the ANO5 gene. It leads to progressive weakness and wasting of muscles, primarily those around the hips and shoulders.
This test is recommended for individuals showing symptoms like progressive muscle weakness in the hips or shoulders, or those with a family history of LGMD.
The test involves analyzing DNA extracted from a blood sample using Next-Generation Sequencing (NGS) technology to look for mutations in the ANO5 gene.
A positive result confirms the presence of a mutation in the ANO5 gene associated with LGMD2L. A negative result means no specific mutations were found in the ANO5 gene. Genetic counseling is recommended to interpret results.
Yes, genetic counseling before and after the test is highly recommended to discuss the implications of the test, understand the results, and explore options for the patient and their family.
Turnaround time varies. Please contact the laboratory for the most current estimate.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp